Original InvestigationPrognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by Novartis. All authors have consulted for and received research support from Novartis, sponsor of the PARADIGM-HF trial. Drs. Prescott, Gong, and Shi are employees of Novartis. Professor McMurray’s employer, University of Glasgow, was paid by Novartis for Professor McMurray’s time spent as co-chairman of the PARADIGM-HF trial. Dr. Packer has served as a consultant for Admittance Technologies, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BioControl, CardioKinetix, CardioMEMS, Cardiorentis, Celyad, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda, and ZS Pharma. Dr. Swedberg has received honoraria from Novartis for sponsored lectures; has served as a consultant for AstraZeneca and Amgen and he has also received research support from Servier. Dr. Desai has served as a consultant for St. Jude Medical, Relypsa, Sanofi, and Merck.